Skip to content
Life Sciences Series B Founded 2008

Andes Biotechnologies

Provider of nucleic acid-based drugs for the treatment of solid tumor cancers. It offers a proprietary antisense oligonucleotide that targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. The Company currently has multiple investigational drug candidates in its pipeline targeting various solid tumor cancer indications. Founded in 2008,…

📍 Santiago, Chile · Genomics,

Funding snapshot

Last roundSeries B
Amount$2M
Date15 December 2017
Total raised$16M
Team size4

About

Provider of nucleic acid-based drugs for the treatment of solid tumor cancers. It offers a proprietary antisense oligonucleotide that targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. The Company currently has multiple investigational drug candidates in its pipeline targeting various solid tumor cancer indications. Founded in 2008, headquartered in Santiago, Chile. The company has raised $16. The company operates in Life Sciences > Genomics, Life Sciences > Gene Therapy, High Tech > Nanotechnology, Life Sciences > Oncology. Its business models include Nanotechnology > Nanotools > Genomics > RNA Sequencing, Oncology > Drugs > Diversified, Genomics > Enabling Technologies > Technology Platforms > RNA interference. Founded in 2008. Headquartered in Chile, Santiago. The company has raised funding at the Series B stage. Backed by investors including Aurus, Austral Capital, Prisma Group.

Business model

Nanotechnology > Nanotools > Genomics > RNA Sequencing,

Oncology > Drugs > Diversified,

Genomics > Enabling Technologies > Technology Platforms > RNA interference

Institutional investors

Aurus Austral Capital Prisma Group

Latest coverage

No articles yet.

Raising like Andes Biotechnologies?

Analyze your pitch deck before your next raise.

Analyze My Deck →